Table 2.

Cox proportional hazard model of discontinuation of Gla-300 among COACH participants compared with non-COACH patients (overall sample)

Variable	Coefficient	HR	95% CI		P value
			Lower limit	Upper limit
COACH participation	−0.517	0.596	0.461	0.771	<0.0001
CCI score	0.157	1.169	1.000	1.368	0.0502
Physician specialization at index
Endocrinologist	0.556	1.744	0.621	4.899	0.2912
PCP/FP/GP/IM	0.269	1.309	0.486	3.525	0.5944
Preindex hospitalization	0.614	1.847	1.055	3.234	0.0316
Rebate marker	0.471	1.601	0.928	2.762	0.0907
Preindex hypoglycemia event	0.118	1.126	0.425	2.981	0.8115
Preindex antidiabetes drug use
Biguanides	−0.147	0.863	0.613	1.215	0.3991
DPP-4 inhibitors	−0.081	0.922	0.556	1.530	0.7532
Fixed-dose combination OADs	−0.267	0.766	0.461	1.272	0.3026
SGLT2 inhibitors	0.131	1.140	0.742	1.75	0.5505
Sulfonylureas	−0.156	0.856	0.602	1.216	0.3843
TZDs	−0.254	0.776	0.413	1.457	0.4299
GLP-1 RAs	−0.653	0.520	0.343	0.790	0.0022
RAIs	0.029	1.030	0.662	1.602	0.8971
Preindex comorbidities
Anxiety	−0.783	0.457	0.208	1.001	0.0504
Coronary artery disease	0.308	1.361	0.765	2.422	0.2949
Depression	0.195	1.215	0.648	2.279	0.5435
Diabetic neuropathy	−0.339	0.712	0.456	1.112	0.1354
Dyslipidemia	0.274	1.315	0.942	1.835	0.1076
Hypertension	0.020	1.020	0.722	1.443	0.9090
Renal impairment	−0.095	0.909	0.513	1.613	0.7453
Stroke/TIA	0.736	2.087	0.757	5.755	0.1549

CCI, Charlson Comorbidity Index; DPP-4, dipeptidyl peptidase-4; FP, family practitioner; GLP-1 RA, glucagon-like peptide-1 receptor agonist; Gla-300, insulin glargine 300 U/mL; GP, general practitioner; IM, internal medicine; OAD, oral antidiabetes drug; PCP, primary care provider; RAI, rapid-acting insulin; SGLT2, sodium glucose co-transporter 2; TIA, transient ischemic attack; TZD, thiazolidinedione.